Home
overview
With the globalization of the pharmaceutical marketplace creating opportunities in previously untapped business areas, how can you make sure your company is ready to take advantage of these new markets? At SMi we have the answer with our latest international conference.

‘Emerging Pharmaceutical Markets’, taking place on the 15th & 16th October 2001 at the Hatton, London, will deliver all the information you need to help you make the most of the latest opportunities in emerging markets. Also, as you’ll hear all this information in just two days, it will save you time as well!

Emerging Pharmaceutical Markets offers you a top-level forum to discuss the ‘hot’ topics on this subject. The conference will offer practical advice through case studies and presentations to make sure you are up to date with the latest issues and developments.

Our speakers at this conference, like Alan Knox of AstraZeneca; Dr Sandy Chalmers of GlaxoSmithKline and Anna Jenoevari of Eli Lilly, are experts in their fields and will offer practical insights on how to best utilise the opportunities in emerging markets. They will be discussing key topics such as:

· Marketing issues in Emerging Markets

· Case studies of the opportunities in each market

· How to value a partnership with an existing company in a new market

· Regulatory issues in emerging markets

· Generic and patenting rights in non-western markets

· Pharmaceutical wholesale & distribution in emerging markets

There will, of course, be plenty of networking opportunities, allowing you to catch up with colleagues from all over the world.

Conference programme

9:00 Registration and Coffee

9:30 Chairman's Opening Remarks

Robert Moran

Robert Moran, President, Plexus Ventures

9:40 EXPLORING THE POTENTIAL VALUE OF EMERGING MARKETS

Sarah Payne

Sarah Payne, Principal Consultant, PricewaterhouseCoopers

  • What are the issues facing healthcare in emerging markets
  • How are these markets going to change?
  • What does this mean for the pharmaceutical industry?
  • 10:20 GLOBALISING THE PHARMACEUTICAL MARKETPLACE

    Dr Maureen Higgins and Roger Joby

    Dr Maureen Higgins and Roger Joby, Global Director of Business Development and Senior Director of Project Planning and Finance, CroMedica

  • Going global: strategy for success
  • Developing a knowledge-based culture
  • Project managing global contracts
  • Cost of globalisation
  • Expanding into emerging markets
  • 11:00 Morning Coffee

    11:20 THE DEVELOPING PHARMA CUSTOMER

    Richard Clifford

    Richard Clifford, Consultant, Promar International

  • Building bridges to the developing world
  • Overcoming the barriers to trust and goodwill
  • Working with the new pharmaceutical customer: Medecins Sans Frontiers, WHO and the World Bank
  • The triple bottom line for pharmaceutical companies: coming off the Sindex
  • Merging need with want to deliver the corporate bottom line
  • 12:00 MARKETING IN EMERGING MARKETS

    Alan Knox

    Alan Knox, Head of Marketing, AstraZeneca

  • Leading a ‘marketing consultancy’ to support emerging markets
  • Marketing planning and portfolio management
  • Segmenting the market: internal and external customers
  • Identifying markets needs: cross cultural tailored approach
  • Transfer of knowledge and skill base into emerging markets

    Understanding the markets: global vs. regional vs. local marketing

  • Cross-functional project teams to maximise the marketing plans

    Implementing an effective marketing strategy in emerging markets

  • 12:40 Lunch

    14:00 WHOLESALE AND DISTRIBUTION IN EMERGING MARKETS

    Patrick Fraser

    Patrick Fraser, Senior Executive to Corporate Development, Alliance UniChem

  • Barriers to distribution in emerging markets
  • Where do you start?
  • Current operation of the pharmaceutical market: a collection of individual national markets
  • Emerging trends in the pharmaceutical supply sector
  • Keys to success in the wholesale market
  • 14:40 CROATIA: A MARKET IN TRANSITION

    Dr Dario Naletilic

    Dr Dario Naletilic, General Manager, Croatia, GlaxoSmithKline

  • Developments in the pharmaceutical sector
  • Overcoming problems encountered by foreign pharmaceutical producers
  • Potential of the Croatian pharma market
  • Legal and regulatory framework and the drug registration process
  • Barriers to trade for foreign pharma companies
  • The impact of the reimbursement policy
  • 15:20 Afternoon Tea

    15:40 THE RUSSIAN PHARMACEUTICAL MARKET

    Gerald Schuh

    Gerald Schuh, General Manager, Novartis Pharma Russia

  • Overview of the Russian pharmaceutical market
  • Driving forces for market evolution
  • Key trends in the Russian pharmamarket
  • Markets structure- Domestic production versus imports
  • Is investment worth the risk
  • Expected structure changes by 2005
  • 16:20 THE POLISH MARKET

    Robert Moran

    Robert Moran, President, Plexus Ventures

  • Why is Poland strategically important in Eastern Europe?
  • What is the status and potential of the Rx market in Poland?
  • What are the complexities of the Polish market?
  • How has a Polfa Kuntno Pharmaceutical Company, -a national firm-positioned itself to compete?
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Anand Tharmaratnam

    Dr Anand Tharmaratnam, Director Business and Clinical Development, Indian Ocean Region, Quintiles Transnational

    9:10 EXPANSION INTO CHINA

    Dr Qi Bao

    Dr Qi Bao, Senior Consultant & Pharmaceuticals Manager, China Concept Consulting

  • How China has the potential to be one of the largest pharmaceutical markets
  • Why invest?
  • Opportunities for Western companies in China
  • Could China be the market in which to launch innovative new products? Why?
  • The creation of niche markets through the education of patients and establishing demand where there was previously none
  • The implications of the changing economic status on disease patterns and the pharma market
  • 9:40 SUCCESSFUL PARTNERING INTO EMERGING MARKETS

    Dr Stephen Castle

    Dr Stephen Castle, Managing Director, Mattson Jack Group, Europe

  • Why joint ventures are an effective method for entering an emerging market
  • Identifying needs, gaps and fillers
  • Partner possibilities
  • Financial implications
  • The structure of successful collaborations
  • Risk assessment
  • 10:20 THE LEGAL ISSUES INVOLVED IN ALLIANCES IN EMERGING MARKETS

    Paul Ranson

    Paul Ranson, Partner, PharmaLaw & Consultant, Simmons and Simmons

  • Scope of the agreement
  • Performance obligations of the parties
  • Liability, warranties, indemnities and insurance
  • Termination and the effects of termination
  • Competition law issues
  • Dispute resolution
  • 11:00 Morning Coffee

    11:20 INDIA AS A CENTRE FOR GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT

    Dr Anand Tharmaratnam

    Dr Anand Tharmaratnam, , Director Business & Clinical Development, Indian Ocean Region, Quintiles Transnational

  • Background of the Indian pharmaceutical industry and the emergence of R+D
  • Why India as a research and development destination?
  • Future opportunities for pharmaceutical companies in India
  • 12:00 BIOTECH AND VACCINES IN THE DEVELOPING WORLD

    Dr Christian Loucq

    Dr Christian Loucq, Business Director Vaccines, Rhein Biotech

  • Overview of what is today the biotech and vaccines industry in the developing world
  • Needs and requirements of developing countries
  • Problems faced by the biotech and vaccines industry
  • Is there a need for a biotech and vaccine industry in the developing world
  • The cases of Korea, China and India
  • You have diecided to go for it: here is some advice

    The future?

  • 12:40 Lunch

    14:00 CENTRAL AND EASTERN EUROPE: FERTILE GROUND FOR CLINICAL TRIALS?

    Dr Lillian Natorff

    Dr Lillian Natorff, Vice President, Clinical Research & Medical Director, Pharm-Olam International

  • Market growth in CEE Clinical trials
  • Specific features of the population (epidemiology compliance, stability, organisation of the health service)
  • Regulatory and EC issues
  • Investigator/ Patient motivation
  • Cost of conducting clinical trials in the region
  • Quality of data in Western Europe versus CEE countries
  • 14:40 PATENT PROTECTION IN EMERGING MARKETS

    Simon Harper

    Simon Harper, Senior Associate, Lovells, London

  • The General Agreement on Tariffs and Trade (GATT)
  • Trade Related Intellectual Property Rights (TRIPS)
  • Patent exclusivity in developing countries: how much protection is provided?
  • Problems for multinational pharmaceutical companies and the concept of exhaustion
  • Special focus on protection in the CEEC in the run-up to EU accession
  • 15:20 Afternoon Tea

    15:40 REGULATORY SYSTEMS IN EMERGING MARKETS

    Anna Jenoevari

    Anna Jenoevari, Senior Area Regulatory Advisor, Eli Lilly

  • Emerging market regulatory overview: requirements, issues in major regions
  • ‘Inheriting’ regulatory systems vs. future trends
  • Working toward global harmony
  • Current status and future directions of the ICH process
  • 16:20 DATA PRIVACY ISSUES

    Dr Sandy Chalmers

    Dr Sandy Chalmers, Data Privacy Advisor, GlaxoSmithKline

  • Personal data control issues in emerging markets
  • The EC Data Protection Directive
  • US developments including evolving health information regulations
  • Overview of the legislation developing in other countries
  • Conditions for Data Transfer from Europe into emerging markets
  • Remote data processing unit challenges
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.